REPLACE 2017-08-15T20:45:13+00:00

Clinical Trials

Aug. 15, 2017

BAY63-2521 REplacing PDE-5i therapy evaLuated Against Continued PDE-5i therapy

  • Study Sponsor: Bayer AG
  • Institution: Bayer U.S. LLC
  • Start Date: Thursday, December 1, 2016
  • End Date: Tuesday, July 31, 2018
  • Design: Background treatment allowed
    Open label
  • Age range (years): from 18 to 75
  • Type of PH
    • IPAH
    • Heritable – APAH
    • CTD – APAH
    • CHD – APAH
    • PoPH – APAH
    • Toxic – APAH
  • Study Duration for individual patient: 24 weeks
  • Contact: clinical‐trials‐contact@bayerhealthcare.com
  • Listing on clinicaltrials.gov